251 related articles for article (PubMed ID: 10471426)
1. Remacemide hydrochloride: a double-blind, placebo-controlled, safety and tolerability study in patients with acute ischemic stroke.
Dyker AG; Lees KR
Stroke; 1999 Sep; 30(9):1796-801. PubMed ID: 10471426
[TBL] [Abstract][Full Text] [Related]
2. A multicenter randomized controlled trial of remacemide hydrochloride as monotherapy for PD. Parkinson Study Group.
Neurology; 2000 Apr; 54(8):1583-8. PubMed ID: 10762497
[TBL] [Abstract][Full Text] [Related]
3. A randomized, double-blind, placebo-controlled, ascending-dose tolerability and safety study of remacemide as adjuvant therapy in Parkinson's disease with response fluctuations.
Clarke CE; Cooper JA; Holdich TA;
Clin Neuropharmacol; 2001; 24(3):133-8. PubMed ID: 11391123
[TBL] [Abstract][Full Text] [Related]
4. Remacemide hydrochloride as an add-on therapy in epilepsy: a randomized, placebo-controlled trial of three dose levels (300, 600 and 800 mg/day) in a B.I.D. regimen.
Jones MW; Blume WT; Guberman A; Lee MA; Pillay N; Weaver DF; Veloso F; Holdich TA
Seizure; 2002 Mar; 11(2):104-13. PubMed ID: 11945097
[TBL] [Abstract][Full Text] [Related]
5. Safety, tolerability, and pharmacokinetics of the N-methyl-D-aspartate antagonist dextrorphan in patients with acute stroke. Dextrorphan Study Group.
Albers GW; Atkinson RP; Kelley RE; Rosenbaum DM
Stroke; 1995 Feb; 26(2):254-8. PubMed ID: 7831698
[TBL] [Abstract][Full Text] [Related]
6. Safety and tolerability study of aptiganel hydrochloride in patients with an acute ischemic stroke.
Dyker AG; Edwards KR; Fayad PB; Hormes JT; Lees KR
Stroke; 1999 Oct; 30(10):2038-42. PubMed ID: 10512904
[TBL] [Abstract][Full Text] [Related]
7. Treatment of acute ischaemic stroke with the low-affinity, use-dependent NMDA antagonist AR-R15896AR. A safety and tolerability study.
Diener HC; AlKhedr A; Busse O; Hacke W; Zingmark PH; Jonsson N; Basun H;
J Neurol; 2002 May; 249(5):561-8. PubMed ID: 12021946
[TBL] [Abstract][Full Text] [Related]
8. Remacemide hydrochloride: a placebo-controlled, one month, double-blind assessment of its safety, tolerability and pharmacokinetics as adjunctive therapy in patients with epilepsy.
Chadwick D; Smith D; Crawford P; Harrison B
Seizure; 2000 Dec; 9(8):544-50. PubMed ID: 11162751
[TBL] [Abstract][Full Text] [Related]
9. A double-blind, placebo-controlled study of remacemide hydrochloride in patients with refractory epilepsy following pre-surgical assessment.
Devinsky O; Vazquez B; Faught E; Leppik IE; Pellock JM; Schachter S; Alderfer V; Holdich TA
Seizure; 2002 Sep; 11(6):371-6. PubMed ID: 12160664
[TBL] [Abstract][Full Text] [Related]
10. Remacemide hydrochloride as an add-on therapy in epilepsy: a randomized, placebo-controlled trial of three dose levels (300, 600 and 1200 mg/day) in a Q.I.D. regimen.
Chadwick DW; Betts TA; Boddie HG; Crawford PM; Lindstrom P; Newman PK; Soryal I; Wroe S; Holdich TA
Seizure; 2002 Mar; 11(2):114-23. PubMed ID: 11945098
[TBL] [Abstract][Full Text] [Related]
11. Mutual interaction between remacemide hydrochloride and carbamazepine: two drugs with active metabolites.
Leach JP; Blacklaw J; Jamieson V; Jones T; Richens A; Brodie MJ
Epilepsia; 1996 Nov; 37(11):1100-6. PubMed ID: 8917061
[TBL] [Abstract][Full Text] [Related]
12. Tolerability of the low-affinity, use-dependent NMDA antagonist AR-R15896AR in stroke patients: a dose-ranging study.
Lees KR; Dyker AG; Sharma A; Ford GA; Ardron ME; Grosset DG
Stroke; 2001 Feb; 32(2):466-72. PubMed ID: 11157184
[TBL] [Abstract][Full Text] [Related]
13. A controlled trial of remacemide hydrochloride in Huntington's disease.
Kieburtz K; Feigin A; McDermott M; Como P; Abwender D; Zimmerman C; Hickey C; Orme C; Claude K; Sotack J; Greenamyre JT; Dunn C; Shoulson I
Mov Disord; 1996 May; 11(3):273-7. PubMed ID: 8723144
[TBL] [Abstract][Full Text] [Related]
14. Mutual interaction between remacemide hydrochloride and phenytoin.
Leach JP; Girvan J; Jamieson V; Jones T; Richens A; Brodie MJ
Epilepsy Res; 1997 Jan; 26(2):381-8. PubMed ID: 9095400
[TBL] [Abstract][Full Text] [Related]
15. Safety, tolerability, and pharmacokinetics of remacemide in children.
Besag FM; Newton RE; Blakey GE; Dean AD
Pediatr Neurol; 2001 May; 24(5):352-6. PubMed ID: 11516608
[TBL] [Abstract][Full Text] [Related]
16. Lack of pharmacokinetic interaction between remacemide hydrochloride and sodium valproate in epileptic patients.
Leach JP; Girvan J; Jamieson V; Jones T; Richens A; Brodie MJ
Seizure; 1997 Jun; 6(3):179-84. PubMed ID: 9203245
[TBL] [Abstract][Full Text] [Related]
17. Aptiganel hydrochloride in acute ischemic stroke: a randomized controlled trial.
Albers GW; Goldstein LB; Hall D; Lesko LM;
JAMA; 2001 Dec; 286(21):2673-82. PubMed ID: 11730442
[TBL] [Abstract][Full Text] [Related]
18. Lubeluzole treatment of acute ischemic stroke. The US and Canadian Lubeluzole Ischemic Stroke Study Group.
Grotta J
Stroke; 1997 Dec; 28(12):2338-46. PubMed ID: 9412611
[TBL] [Abstract][Full Text] [Related]
19. A placebo-controlled, double-blind cross-over trial of adjunctive one month remacemide hydrochloride treatment in patients with refractory epilepsy.
Richens A; Mawer G; Crawford P; Harrison B
Seizure; 2000 Dec; 9(8):537-43. PubMed ID: 11162750
[TBL] [Abstract][Full Text] [Related]
20. Treatment of acute ischemic stroke with piracetam. Members of the Piracetam in Acute Stroke Study (PASS) Group.
De Deyn PP; Reuck JD; Deberdt W; Vlietinck R; Orgogozo JM
Stroke; 1997 Dec; 28(12):2347-52. PubMed ID: 9412612
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
